<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387344</url>
  </required_header>
  <id_info>
    <org_study_id>UNIME_CARD_2</org_study_id>
    <nct_id>NCT04387344</nct_id>
  </id_info>
  <brief_title>Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis</brief_title>
  <official_title>Cardiac Modifications in Transthyretin Cardiac Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Campisi Mariapaola</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac Amyloidosis (CA) is characterized by a long subclinical phase characterized by
      deposition of amyloid fibrils in atria, valves and walls of ventricles. Longitudinal
      dysfunction of the left ventricle (LV) with preserved ejection fraction (EF) is the early
      phase of CA.

      Longitudinal dysfunction mainly involves the LV basal and middle segments with less
      involvement of the distal segments (apical sparing).

      Strain echocardiography (STE) measures myocardial deformation. The technique has been shown
      to be sensitive for early detection of impaired systolic function and for the study of CA.
      Additionally, cardiac efficiency (myocardial work) can be derived from myocardial strain data
      analysis.

      In the year 2018, &quot;RNA interferences&quot; (patisiran and inotersen) were included in the list of
      compassionate therapeutic use programs for exclusive use for the treatment of adult patients
      with hereditary amyloidosis neuropathy. The aim of our study is to evaluate the
      morpho-functional modifications with RNA interferences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transthoracic echocardiographic images are recorded in the available ultrasound units (Vivid
      7 and Vivid 9, GE Ultrasound, Horten, Norways and MyLab - Esaote, Genoa, Italy). The
      diameters and the wall thicknesses are measured according to the insurance of the American
      Society of Echocardiography. The images obtained with apical view and in format 4 bedrooms
      with frame rates (70-80 frames / s) - stored for three cardiac cycles in cine-loop format -
      will be used for evaluate off-line to evaluate left ventricle deformation in the longitudinal
      and radial direction, basalelateral, and top segments (post processing) through software
      already in use and available (Suitestenza, Esaote, Florence, Italy and GE Ultrasound, Horten,
      Norway).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Atrial and Ventricular Walls Dimensions</measure>
    <time_frame>Change from Baseline Wall Thickness to 18 months</time_frame>
    <description>Measurements (mm) of Interatrial Septum, Ventricular Walls, Coumadin Ridge, Mitro-aortic Lamina, Valves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Atrial and Ventricular Strain</measure>
    <time_frame>Change from Baseline Atrial and Ventricular Strain to 18 months</time_frame>
    <description>Mean paired change in myocardial strain (percent) by echocardiographic strain-rate imaging (unitless)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Myocardial Work index of Left Ventricle</measure>
    <time_frame>Change from Baseline Myocardial work to 18 months</time_frame>
    <description>Evaluation of the Global work index (GWI): total work within the area of the LV pressure-strain loops calculated from mitral valve closure to mitral valve opening.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with a diagnosis amyloidosis treated with RNA interferences. A
        diagnosis of cardiac amyloidosis requires left ventricular wall thickness of ≥12 and a
        positive perugini score (grade 2-3) on technetium-99m(99mTc)-diphosphonate (DPD) or
        99mTc-hydroxyl-methylene-diphosphonate (HMDP) bone scintigraphy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of data obtained from historical records of patients who retrospectively met
             the prescriptive (neurological) criteria and received the prescription of the drugs in
             question (RNA interferences) having

          -  Cardiological evaluation (examination ECG, echocardiography) at the time of
             prescription

          -  Cardiological evaluation (examination ECG, echocardiography) evaluated six months
             after therapy,

          -  Cardiological evaluation (examination ECG, echocardiography) evaluated 12-18 months
             after therapy,

        Exclusion Criteria:

          -  it wasn't possible to putatively confirm the reasonable shipment of the innovative
             therapy prescribed

          -  it wasn't possible to putatively confirm the reasonable shipment of conventional
             therapy prescribed (background therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Gianluca Di Bella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Messina, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Cappelli, MD</last_name>
    <phone>+39 055 794 9946</phone>
    <email>cappellifrancesco@inwind.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesco Cappelli, MD</last_name>
      <phone>+39 055 794 9946</phone>
      <email>cappellifrancesco@inwind.it</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Francesco Cappelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS.</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marco Luigetti</last_name>
      <email>marco.luigetti@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Marco Luigetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Di Bella G, Pizzino F, Minutoli F, Zito C, Donato R, Dattilo G, Oreto G, Baldari S, Vita G, Khandheria BK, Carerj S. The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging. 2014 Dec;15(12):1307-15. doi: 10.1093/ehjci/jeu158. Epub 2014 Sep 4. Review.</citation>
    <PMID>25190073</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Bella G, Minutoli F, Piaggi P, Casale M, Mazzeo A, Zito C, Oreto G, Baldari S, Vita G, Pingitore A, Khandheria BK, Carerj S. Usefulness of Combining Electrocardiographic and Echocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects With Transthyretin Gene Mutation. Am J Cardiol. 2015 Oct 1;116(7):1122-7. doi: 10.1016/j.amjcard.2015.07.008. Epub 2015 Jul 16.</citation>
    <PMID>26253999</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Bella G, Minutoli F, Pingitore A, Zito C, Mazzeo A, Aquaro GD, Di Leo R, Recupero A, Stancanelli C, Baldari S, Vita G, Carerj S. Endocardial and epicardial deformations in cardiac amyloidosis and hypertrophic cardiomyopathy. Circ J. 2011;75(5):1200-8. Epub 2011 Mar 17.</citation>
    <PMID>21427499</PMID>
  </results_reference>
  <results_reference>
    <citation>Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferović PM, Barison A, Castiglione V, Vergaro G, Giannoni A, Passino C, Merlini G. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J. 2019 Dec 1;40(45):3699-3706. doi: 10.1093/eurheartj/ehz298.</citation>
    <PMID>31111153</PMID>
  </results_reference>
  <results_reference>
    <citation>Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.</citation>
    <PMID>29972757</PMID>
  </results_reference>
  <results_reference>
    <citation>Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.</citation>
    <PMID>29972753</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Gianluca Di Bella</investigator_full_name>
    <investigator_title>Associate Professor Cardiovascular Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

